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OBJECTIVE—Two independent genome-wide association stud-
ies for type 2 diabetes in Japanese subjects have recently
identiﬁed common variants in the KCNQ1 gene that are strongly
associated with type 2 diabetes. Here we studied whether a
common variant in KCNQ1 would inﬂuence BMI as well as
insulin secretion and action and predict future type 2 diabetes in
subjects from Sweden and Finland.
RESEARCH DESIGN AND METHODS—Risk of type 2 diabe-
tes conferred by KCNQ1 rs2237895 was studied in 2,830 type 2
diabetic case subjects and 3,550 control subjects from Sweden
(Malmo ¨ Case-Control) and prospectively in 16,061 individuals
from the Malmo ¨ Preventive Project (MPP). Association between
genotype and insulin secretion/action was assessed cross-
sectionally in 3,298 nondiabetic subjects from the Prevalence,
Prediction and Prevention of Diabetes (PPP)-Botnia Study and
longitudinally in 2,328 nondiabetic subjects from the Botnia
Prospective Study (BPS). KCNQ1 expression (n  18) and
glucose-stimulated insulin secretion (n  19) were measured in
human islets from nondiabetic cadaver donors.
RESULTS—The C-allele of KCNQ1 rs2237895 was associated
with increased risk of type 2 diabetes in both the Malmo ¨
Case-Control (odds ratio 1.23 [95% CI 1.12–1.34]; P  5.6  10
6)
and the prospective (1.14 [1.06–1.22]; P  4.8  10
4) studies.
Furthermore, the C-allele was associated with decreased insulin
secretion (corrected insulin response [CIR] P  0.013; disposi-
tion index [DI] P  0.013) in the PPP-Botnia Study and in the BPS
at baseline (CIR P  3.6  10
4;D IP  0.0058) and after
follow-up (CIR P  0.0018; DI P  0.0030). C-allele carriers
showed reduced glucose-stimulated insulin secretion in human
islets (P  2.5  10
6).
CONCLUSIONS—A common variant in the KCNQ1 gene is
associated with increased risk of future type 2 diabetes in
Scandinavians, which partially can be explained by an effect on
insulin secretion. Diabetes 58:2409–2413, 2009
R
ecently, two independent genome-wide associa-
tion studies in Japanese subjects have shown
that single nucleotide polymorphisms (SNPs)
in the KCNQ1 gene (rs2074196, rs2237892,
rs2237895, rs2283228, and rs2237897) are associated with
type 2 diabetes (1,2). We have previously replicated asso-
ciation of rs2074196 and rs2237892 reported by Yasuda et
al. (1) in Scandinavian subjects. Here we studied
rs2237895, which is the only of the replicated variants by
Unoki et al. (2) in a Danish population with a minor allele
frequency 5% (43%). KCNQ1 encodes for a voltage-gated
potassium channel that is highly expressed in cardiac
muscle, pancreas, intestine, and kidney. Mutations in the
KCNQ1 gene cause the long QT syndrome and deafness
(3).
Here we studied whether rs2237895 increases risk of
type 2 diabetes and/or affects insulin secretion and action
in several Swedish and Finnish cross-sectional and pro-
spective cohorts including a total of 28,067 individuals.
RESEARCH DESIGN AND METHODS
Characteristics of the study participants are reported in Table 1. Malmo ¨ Case-
Control consisted of 2,830 diabetic case subjects from the Malmo ¨ Diabetes
Registry (4) and 3,550 nondiabetic control subjects from the Malmo ¨ Diet and
Cancer Study (5) in southern Sweden. All case subjects had Scandinavian origin,
age at onset 35 years, C-peptide 0.3 nmol/l, and no GAD antibody. Control
subjects had fasting blood glucose 5.5 mmol/l and A1C 6.0% (6).
The Malmo ¨ Preventive Project (MPP) is a large population-based prospec-
tive study from the city of Malmo ¨, Sweden, consisting of 16,061 nondiabetic
subjects, 2,063 of whom developed type 2 diabetes during a 24.8-year median
follow-up period (7). Diagnosis of diabetes was conﬁrmed from patient
records or fasting plasma glucose 7.0 mmol/l.
The Prevalence, Prediction and Prevention of Diabetes (PPP)-Botnia Study
is a population-based study from the Botnia region of western Finland. The
current study includes 3,298 nondiabetic subjects (fasting plasma glucose
7.0 mmol/l and 2-h plasma glucose 11.1 mmol/l).
The Botnia Study started in 1990 at the west coast of Finland, aiming at
identiﬁcation of genes increasing susceptibility to type 2 diabetes in members
from families with type 2 diabetes (8). The prospective part included 2,770
nondiabetic family members and/or their spouses (1,263 men and 1,507
women; mean age 45 years), 138 of whom developed type 2 diabetes during a
7.7-year (median) follow-up period (9). All subjects were given information
about exercise and healthy diet and subjected at 2- to 3-year intervals to a new
oral glucose tolerance test (OGTT). The current analyses includes 2,328
nondiabetic individuals (fasting plasma glucose 7.0 mmol/l and 2-h plasma
glucose 11.1 mmol/l) with available longitudinal measurements of insulin
secretion and action.
Measurements. In MPP, fasting blood samples were drawn at baseline and
follow-up visit for measurement of plasma glucose. In the PPP-Botnia Study,
blood samples were drawn at 0, 30, and 120 min of the OGTT. In the Botnia
Prospective Study (BPS), blood samples were drawn at 10, 0, 30, 60, and 120
min of the OGTT both at baseline and at follow-up. Insulin sensitivity index
(ISI) from the OGTT was calculated as 10,000/(Pfasting glucose  Pfasting insulin 
mean OGTTglucose  mean OGTTinsulin) (10). The basal homeostasis model
assessment–insulin resistance (HOMA-IR) index was calculated from fasting
insulin and glucose concentrations (http://www.dtu.ox.ac.uk). -Cell function
was assessed as corrected insulin response (CIR) during OGTT (CIR  100 
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diabetes.diabetesjournals.org DIABETES, VOL. 58, OCTOBER 2009 2409insulin30/[glucose30  (glucose303.89)]) or as disposition index (DI), i.e.,
insulin secretion adjusted for insulin sensitivity (DI  CIR  ISI) (11).
Genotyping. Genotyping was performed by an allelic discrimination method
with a TaqMan assay on the ABI 7900 platform (Applied Biosystems, Foster
City, CA). We obtained an average genotyping success rate of 93.2%, and the
average concordance rate, based on 2,944 duplicate comparisons using a
KASPar competitive allele-speciﬁc PCR system (Kbioscience, Hoddesdon,
U.K.), was 99.9%. Hardy-Weinberg equilibrium was fulﬁlled in all studied
populations (P  0.20).
Glucose-stimulated insulin secretion. Islets from 27 human cadaver do-
nors were provided by the Nordic network for clinical islets transplantation by
the courtesy of Olle Korsgren, Uppsala University, Uppsala, Sweden. The
experimental protocol for isolation of islets was approved by the ethics
committee of Uppsala University and performed in accordance with local
institutional and Swedish national regulations.
Puriﬁed islets were collected under a stereomicroscope at room tempera-
ture. The islets were either directly subjected to Affymetrix analysis (see
below) or preincubated for 30 min at 37°C in Krebs Ringer bicarbonate (KRB)
buffer, pH 7.4, supplemented with 10 mmol/l N-2 hydroxyethylpiperazine-N-
2-ethanesulfonic acid, 0.1% BSA, and 1 mmol/l glucose. Each incubation vial
contained 12 islets in 1.0 ml KRB buffer solution and treated with 95% O2/5%
CO2 to obtain constant pH and oxygenation. After preincubation, the buffer
was changed to a medium containing either 1 or 20 mmol/l glucose. The islets
were then incubated for1ha t37°C in a metabolic shaker (30 cycles per min).
Immediately after incubation an aliquot of the medium was removed for
measurement of insulin using a radioimmunoassay (Linco Research, Saint
Charles, MO). Glucose-stimulated insulin secretion is expressed as fold
change of insulin release from the islets by comparing release at 20 mmol/l
with release using the 1 mmol/l glucose medium.
Expression of the KCNQ1 gene in human pancreatic islets. Total RNA
was isolated with the AllPrep DNA/RNA Mini Kit (Qiagen, Hilden, Germany).
RNA quality and concentration were measured using an Agilent 2100 bioana-
lyzer and Nanodrop ND-1000 equipment, respectively.
The microarrays were performed following the Affymetrix standard proto-
col. Brieﬂy, total RNA 100–300 ng was processed following the GeneChip
Expression 3-Ampliﬁcation Reagents One-cycle cDNA Synthesis Kit instruc-
tions (Affymetrix, Santa Clara, CA) to produce double-stranded cDNA. This
was used as a template to generate biotin-targeted cRNA following manufac-
turer’s speciﬁcations. Additionally, 15 	g of the biotin-labeled cRNA was
fragmented to strands between 35 and 200 bases in length, 10 	g of which was
hybridized onto the GeneChip Human Gene 1.0 ST whole transcript based–
assay overnight in the GeneChip Hybridization Oven 6400 using standard
procedures. The arrays were washed and stained in a GeneChip Fluidics
Station 450. Scanning was carried out with the GeneChip Scanner 3000, and
image analysis was performed using GeneChip Operating Software. The array
data were summarized and normalized with robust multiarray analysis
method using the software Expression Console (Affymetrix).
Statistical analyses. Data are presented as means 
 SD and, if not normally
distributed, as median (interquartile range). The risk of developing type 2
diabetes is expressed as odds ratio (OR) using logistic regression analyses
adjusted for age, sex, and BMI. Because men and women in MPP were
included at different time periods, we adjusted for this using inclusion period
and an interaction term inclusion period  sex. Genotype-phenotype corre-
lations were studied using linear regression analyses adjusted for age, sex, and
BMI (where appropriate). A robust variance estimate was used to adjust for
within-pedigree dependence in BPS, treating each pedigree as an independent
entity when calculating the variance of the estimates. Nonnormally distributed
variables (insulin, HOMA-IR, ISI, CIR, and DI) were logarithmically (natural)
transformed for analyses. For analysis of data from human pancreatic islets,
one-way ANOVA was used to assess association between genotype and
phenotype (expression and insulin secretion) and Spearman’s rank correla-
tion test was used to assess association of KCNQ1 mRNA level with insulin
release. All statistical analyses were performed under an additive model with
the Statistical Package for the Social Sciences v. 16.0 (SPSS, Chicago, IL) and
STATA SE v. 10.1 (StataCorp, College Station, TX). Meta-analyses were
performed with Metan using ﬁxed-effect models using the inverse variance
method. Inter-study heterogeneity was tested by Cochran Q and the I
2
measure as implemented in STATA. Two-sided P values 0.05 were consid-
ered statistically signiﬁcant.
RESULTS
Effect of KCNQ1 rs2237895 on risk of type 2 diabetes
and glucose levels. In the Malmo ¨ Case-Control study, the
C-allele of KCNQ1 rs2237895 was more frequent in case
subjects than in control subjects (0.44 and 0.40, respec-
tively; 
2 P  9.5  10
6), yielding an age-, sex-, and
BMI-adjusted OR of 1.23 (95% CI 1.12–1.34; P  5.6 
10
6). The same SNP (C-allele) predicted future type 2
diabetes in the MPP (1.14 [1.06–1.22]; P  4.7  10
4). In
the MPP, nondiabetic carriers of the C-allele showed
higher fasting plasma glucose levels both at baseline (P 
0.033) and after the 25-year follow-up period (P  1.2 
10
6) (Table 2). Also in the PPP-Botnia study, the C-allele
carriers showed elevated fasting plasma glucose concen-
trations (P  0.0067) (Table 2).
Effect of KCNQ1 rs2237895 on BMI, insulin secre-
tion, and action. There was no effect of the SNP on BMI
in any of the cohorts. The C-allele carriers of the PPP-
Botnia Study showed lower insulin response to glucose at
30 min during OGTT (CIR P  0.013, DI P  0.013; Table
2, Fig. 1A and B). Also in BPS, the C-allele was associated
with reduced -cell function at baseline (CIR P  3.6 
10
4;D IP  0.0058) and at follow-up (CIR P  0.0018; DI
P  0.0030) (Table 2, Fig. 1C and D). The KCNQ1
rs2237895 had no effect on insulin sensitivity estimated by
HOMA-IR or ISI during OGTT.
Expression of KCNQ1 and glucose-stimulated insulin
secretion in human pancreatic islets. We also analyzed
KCNQ1 mRNA from microarray data on pancreatic islets
from 18 nondiabetic human cadaver organ donors in
TABLE 1
Characteristics of the study participants
Malmö Case-Control
MPP PPP-Botnia Study BPS Case subjects Control subjects
n (men/women) 2,830 (1,667/1,163) 3,550 (1,340/2,210) 16,061 (10,416/5,645) 3,298 (1,538/1,760) 2,328 (1,065/1,263)
Age (years) 57.9 
 11.5 57.5 
 6.0 45.5 
 6.9 48.5 
 15.9 45.5 
 13.6
BMI (kg/m
2) 29.6 
 5.5 25.1 
 3.6 24.3 
 3.3 26.2 
 4.2 25.6 
 3.9
Pfasting glucose (mmol/l) 11.89 
 4.34 4.78 
 0.36 5.45 
 0.56 5.16 
 0.55 5.52 
 0.57
HOMA-IR 3.08 (2.38) 0.67 (0.46) 0.95 (1.16) 0.60 (0.50) 0.58 (0.40)
CIR — — 149 (127) 157.7 (163.3) 112.2 (124.6)
ISI — — 165 (170) 144.9 (111.9) 147.6 (111.3)
DI — — 23,393 (27,302) 22,535 (25,855) 15,717 (18,334)
Follow-up time
(years) — — 24.8 (4.7) — 7.6 (5.2)
KCNQ1 rs2237895
RAF 0.44 0.40 0.41 0.49 0.47
Data are means 
 SD or median (interquartile range) unless otherwise indicated. Baseline characteristics are shown for MPP and BPS. RAF,
risk allele frequency.
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KCNQ1 expression in human islets among carriers of
different genotypes (P  0.65). Information on glucose-
stimulated insulin secretion at 1 and 20 mmol/l of glucose
was available for islets from 19 donors. Risk allele carriers
showed lower glucose-stimulated insulin secretion mea-
sured as fold change of insulin release from the islets at 1
and 20 mmol/l glucose, i.e., stimulation index (P  2.5 
10
6) (Fig. 1E). These results remained unchanged when
stimulation index was adjusted for the basal insulin secre-
tion at 1 mmol/l of glucose (P  4.7  10
5; supplementary
Fig. 1, available online at http://diabetes.diabetesjournals.
org/cgi/content/full/db09-0246/DC1). We could not observe
any correlation between KCNQ1 expression and glucose-
stimulated insulin secretion (n  10, r  0.115, P  0.75).
DISCUSSION
The key ﬁnding of the present study was that a common
variant rs2237895 in the KCNQ1 gene was associated with
increased risk of future type 2 diabetes because of impair-
ment of -cell function. Variants in KCNQ1 have been
associated with type 2 diabetes predominantly in Asian
subjects. Most of these studies had a case subject–control
subject design that tends to overestimate the risk of a SNP
because case subjects and control subjects usually repre-
TABLE 2
Metabolic effects of KCNQ1 rs2237895 in nondiabetic individuals from the studied populations
Genotype Additive model
n AA AC CC  SE P
MPP
Baseline
BMI (kg/m
2) 12,326 24.0 
 3.1 24.0 
 3.1 24.0 
 3.0 0.035 0.040 0.37
Fasting plasma glucose (mmol/l) 12,328 5.41 
 0.55 5.42 
 0.54 5.42 
 0.55 0.015 0.007 0.033
2-h plasma glucose (mmol/l) 6,718 6.28 
 1.58 6.36 
 1.65 6.36 
 1.67 0.050 0.026 0.052
Follow-up
BMI (kg/m
2) 12,271 26.9 
 3.9 26.8 
 3.9 26.8 
 3.9 0.023 0.051 0.65
Fasting plasma glucose (mmol/l) 12,327 5.44 
 0.54 5.46 
 0.55 5.50 
 0.55 0.033 0.007 1.2  10
6
PPP-Botnia Study
BMI (kg/m
2) 2,991 26.1 
 4.0 26.2 
 4.2 26.1 
 4.3 0.033 0.102 0.75
Fasting plasma glucose (mmol/l) 2,994 5.13 
 0.53 5.17 
 0.56 5.20 
 0.56 0.038 0.014 0.0067
2-h plasma glucose (mmol/l) 2,976 5.08 
 1.53 5.17 
 1.56 5.23 
 1.65 0.074 0.038 0.053
ISI 2,838 145 (109) 144 (111) 144 (112) 0.001 0.013 0.95
HOMA-IR 2,939 0.60 (0.50) 0.60 (0.50) 0.60 (0.50) 0.001 0.014 0.93
CIR 2,849 166 (180) 155 (158) 157 (161) 0.048 0.019 0.013
CIR adjusted for ISI 0.051 0.019 0.0073
DI 2,814 23,464 (27,419) 22,366 (25,013) 21,866 (24,716) 0.052 0.021 0.013
BPS
Baseline
BMI (kg/m
2) 2,123 25.8 
 3.9 25.4 
 3.9 25.7 
 3.9 0.065 0.119 0.59
Fasting plasma glucose (mmol/l) 2,128 5.59 
 0.58 5.49 
 0.56 5.53 
 0.58 0.029 0.022 0.19
2-h plasma glucose (mmol/l) 2,128 6.10 
 1.45 6.08 
 1.45 6.27 
 1.50 0.072 0.048 0.13
ISI 2,128 144 (106) 154 (114) 146 (109) 0.014 0.018 0.42
HOMA-IR 2,128 0.61 (0.42) 0.57 (0.37) 0.58 (0.43) 0.015 0.016 0.34
CIR 2,128 118 (131) 115 (126) 96 (117) 0.089 0.025 3.6  10
4
CIR adjusted for ISI 0.083 0.024 7.2  10
4
DI 2,128 15,934 (19,260) 16,663 (19,049) 14,102 (16,413) 0.075 0.027 0.0058
Follow-up
BMI (kg/m
2) 2,068 26.8 
 4.2 26.4 
 4.0 26.8 
 4.3 0.051 0.136 0.71
Fasting plasma glucose (mmol/l) 2,128 5.29 
 0.57 5.30 
 0.55 5.33 
 0.60 0.032 0.018 0.077
2-h plasma glucose (mmol/l) 2,128 5.77 
 1.76 5.85 
 1.67 6.00 
 1.77 0.127 0.050 0.011
ISI 2,127 101 (94) 102 (85) 96 (93) 0.003 0.019 0.89
HOMA-IR 2,125 0.97 (0.87) 0.93 (0.76) 0.96 (0.90) 0.010 0.018 0.58
CIR 2,128 160 (184) 142 (160) 130 (140) 0.086 0.027 0.0018
CIR adjusted for ISI 0.087 0.027 0.0013
DI 2,127 15,563 (21,424) 14,322 (18,304) 13,299 (17,404) 0.089 0.030 0.0030
Meta analysis
BMI (kg/m
2) 0.41
Fasting plasma glucose (mmol/l) 0.0078
2-h plasma glucose (mmol/l) 0.0021
ISI 0.58
HOMA-IR 0.57
CIR 3.0  10
5
CIR adjusted for ISI 2.7  10
5
DI 2.5  10
4
Data are means 
 SD or median (interquartile range) unless otherwise indicated.  and SE from linear regression analysis adjusted for age,
sex, BMI, and within-pedigree dependence (BPS) denote the effect size by each C-allele (additive model) on phenotype. Meta-analysis
includes the PPP-Botnia Study and the BPS at baseline. P values  0.05 are in boldface.
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This is to our knowledge the ﬁrst population-based study
using a prospective design showing that the SNP indeed
increases risk of future type 2 diabetes and that this is due
to failing -cell function.
Although common variants in KCNQ1 increase suscep-
tibility to type 2 diabetes in both Asians and Europeans,
the frequency of the risk allele of most SNPs is much
higher in Europeans than in Asians (92–96% in Europeans
compared with 59–69% in Japanese), which most likely
explains why SNPs in this gene were not signiﬁcantly
associated with type 2 diabetes in the initial European
genome-wide association studies. In this regard, SNP
rs2237895 represents an exception because the frequency
of the risk allele was similar in Scandinavians (43%) and in
Asians (36%) (1). The ORs for type 2 diabetes were also
quite similar across studies: 1.23 in the current study, 1.31
in Asians (1), and 1.24 in Danes (2).
We also provide compelling evidence that the risk
C-allele is associated with deterioration of -cell function
over time in the BPS, which thereby conﬁrms and extends
our previous observation of an association between the
risk allele of another SNP (rs2237892) in KCNQ1 and
impaired insulin secretion (P  0.024) (1).
In analogy with Kir 6.2 (KCNJ11), KCNQ1 is an ATP-
dependent potassium channel that is also expressed in
human islets. It has been ascribed a role in insulin secre-
tion, most likely through alterations in the membrane
repolarization potential of the pancreatic -cells. Indeed,
we found that risk allele carriers had lower glucose-
FIG. 1. Effect of KCNQ1 rs2237895 on -cell function. Data are
represented as the mean of the unadjusted logarithmic (natural)
values for corrected insulin response and DI. Error bars denote SE of
the mean. A: Decline in CIR with each C-allele (P  0.013) in the
PPP-Botnia Study. B: Decrease in DI with each C-allele (P  0.013) in
the PPP-Botnia Study. C: CIR in various genotype carriers at baseline
and at follow-up in the BPS. The C-allele carriers had lower CIR at
baseline (P  3.6  10
4) that remained lower at follow-up (P 
0.0018). D: DI in various genotype carriers at baseline and at follow-up
in the BPS. The C-allele carriers had lower DI at baseline (P  0.0058)
that remained lower at follow-up (P  0.0030). E: Glucose-stimulated
insulin secretion as fold change in insulin release at high (20 mmol/l)
compared with low (1 mmol/l) glucose concentration from human islets
in various genotype carriers. C-allele carriers showed lower glucose-
stimulated insulin secretion (P  2.5  10
6). KCNQ1 rs2237895
genotypes: AA, homozygous major allele carriers; AC, heterozygous;
CC, homozygous minor (risk) allele carriers.
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demonstrate a signiﬁcant effect of the genotype on expres-
sion of the KCNQ1 gene in human islets, suggesting that
the effect could be mediated through effects on splicing,
translation, or posttranslational modiﬁcations. However,
we cannot rule out that this lack of effect is due to low
power because of limited number of human islets. In
conclusion, we provide conclusive evidence that common
variants in the KCNQ1 gene increase risk of future type 2
diabetes by causing impaired -cell function.
ACKNOWLEDGMENTS
These studies were supported by grants from the Swedish
Research Council including a Linne ´ Grant (31475113580),
the Heart and Lung Foundation, the Swedish Diabetes
Research Society, the European Community’s Seventh
Framework Programme (FP7/2007-2013), the ENGAGE
project, Grant HEALTH-F4-2007-201413, a Nordic Centre
of Excellence Grant in Disease Genetics, the Diabetes
Programme at Lund University, the Påhlsson Foundation,
the Crafoord Foundation, the Knut and Alice Wallenberg
Foundation, the European Foundation for the Study of
Diabetes (EFSD), the Finnish Diabetes Research Society,
the Sigrid Juselius Foundation, the Folkha ¨lsan Research
Foundation, the Signe and Ane Gyllenberg Foundation, the
Swedish Cultural Foundation in Finland, the Ollqvist
Foundation, the Foundation for Life and Health in Finland,
Jakobstad Hospital, the Medical Society of Finland, the
Na ¨rpes Research Foundation, and the Vasa and Na ¨rpes
Health Centers.
These studies were also supported by the Novo Nordisk
Foundation. No other potential conﬂicts of interest rele-
vant to this article were reported.
Human islets were provided by the Nordic network for
clinical islets transplantation by the courtesy of Dr. Olle
Korsgren, Uppsala, Sweden. We thank the patients for
their participation and the Botnia Study Group for clini-
cally studying the patients.
REFERENCES
1. Yasuda K, Miyake K, Horikawa Y, Hara K, Osawa H, Furuta H, Hirota Y,
Mori H, Jonsson A, Sato Y, Yamagata K, Hinokio Y, Wang HY, Tanahashi T,
Nakamura N, Oka Y, Iwasaki N, Iwamoto Y, Yamada Y, Seino Y, Maegawa
H, Kashiwagi A, Takeda J, Maeda E, Shin HD, Cho YM, Park KS, Lee HK,
Ng MC, Ma RC, So WY, Chan JC, Lyssenko V, Tuomi T, Nilsson P, Groop
L, Kamatani N, Sekine A, Nakamura Y, Yamamoto K, Yoshida T, Tokunaga
K, Itakura M, Makino H, Nanjo K, Kadowaki T, Kasuga M. Variants in
KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nat
Genet 2008;40:1092–1097
2. Unoki H, Takahashi A, Kawaguchi T, Hara K, Horikoshi M, Andersen G, Ng
DP, Holmkvist J, Borch-Johnsen K, Jorgensen T, Sandbaek A, Lauritzen T,
Hansen T, Nurbaya S, Tsunoda T, Kubo M, Babazono T, Hirose H, Hayashi
M, Iwamoto Y, Kashiwagi A, Kaku K, Kawamori R, Tai ES, Pedersen O,
Kamatani N, Kadowaki T, Kikkawa R, Nakamura Y, Maeda S. SNPs in
KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian
and European populations. Nat Genet 2008;40:1098–1102
3. Splawski I, Shen J, Timothy KW, Lehmann MH, Priori S, Robinson JL, Moss
AJ, Schwartz PJ, Towbin JA, Vincent GM, Keating MT. Spectrum of
mutations in long-QT syndrome genes: KVLQT1, HERG, SCN5A, KCNE1,
and KCNE2. Circulation 2000;102:1178–1185
4. Lindholm E, Agardh E, Tuomi T, Groop L, Agardh CD. Classifying diabetes
according to the new WHO clinical stages. Eur J Epidemiol 2001;17:983–
989
5. Hedblad B, Nilsson P, Engstrom G, Berglund G, Janzon L. Insulin resis-
tance in non-diabetic subjects is associated with increased incidence of
myocardial infarction and death. Diabet Med 2002;19:470–475
6. Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, Chen H, Roix JJ,
Kathiresan S, Hirschhorn JN, Daly MJ, Hughes TE, Groop L, Altshuler D,
Almgren P, Florez JC, Meyer J, Ardlie K, Bengtsson Bostrom K, Isomaa B,
Lettre G, Lindblad U, Lyon HN, Melander O, Newton-Cheh C, Nilsson
P, Orho-Melander M, Rastam L, Speliotes EK, Taskinen MR, Tuomi
T, Guiducci C, Berglund A, Carlson J, Gianniny L, Hackett R, Hall L,
Holmkvist J, Laurila E, Sjogren M, Sterner M, Surti A, Svensson M, Svens-
son M, Tewhey R, Blumenstiel B, Parkin M, Defelice M, Barry R, Brodeur
W, Camarata J, Chia N, Fava M, Gibbons J, Handsaker B, Healy C, Nguyen
K, Gates C, Sougnez C, Gage D, Nizzari M, Gabriel SB, Chirn GW, Ma Q,
Parikh H, Richardson D, Ricke D, Purcell S. Genome-wide association
analysis identiﬁes loci for type 2 diabetes and triglyceride levels. Science
2007;316:1331–1336
7. Berglund G, Nilsson P, Eriksson KF, Nilsson JA, Hedblad B, Kristenson H,
Lindgarde F. Long-term outcome of the Malmo preventive project: mortal-
ity and cardiovascular morbidity. J Intern Med 2000;247:19–29
8. Groop L, Forsblom C, Lehtovirta M, Tuomi T, Karanko S, Nissen M,
Ehrnstrom BO, Forsen B, Isomaa B, Snickars B, Taskinen MR. Metabolic
consequences of a family history of NIDDM (the Botnia study): evidence
for sex-speciﬁc parental effects. Diabetes 1996;45:1585–1593
9. Lyssenko V, Jonsson A, Almgren P, Pulizzi N, Isomaa B, Tuomi T, Berglund
G, Altshuler D, Nilsson P, Groop L. Clinical risk factors, DNA variants, and
the development of type 2 diabetes. N Engl J Med 2008;359:2220–2232
10. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral
glucose tolerance testing: comparison with the euglycemic insulin clamp.
Diabetes Care 1999;22:1462–1470
11. Hanson RL, Pratley RE, Bogardus C, Narayan KM, Roumain JM, Impera-
tore G, Fagot-Campagna A, Pettitt DJ, Bennett PH, Knowler WC. Evalua-
tion of simple indices of insulin sensitivity and insulin secretion for use in
epidemiologic studies. Am J Epidemiol 2000;151:190–198
A. JONSSON AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 58, OCTOBER 2009 2413